![Radiological findings of inflammatory myofibroblastic tumor. Abdominal computed tomography shows a well-circumscribed, heterogeneously enhancing mass in the retroperitoneum.

Choi JH. Inflammatory Myofibroblastic Tumor: An Updated Review. Cancers. 2025; 17(8):1327. https://doi.org/10.3390/cancers17081327](attachment:6df96245-3764-4f9a-822c-b2f3283cfad5:cancers-17-01327-g001.png)

Radiological findings of inflammatory myofibroblastic tumor. Abdominal computed tomography shows a well-circumscribed, heterogeneously enhancing mass in the retroperitoneum.

Choi JH. Inflammatory Myofibroblastic Tumor: An Updated Review. Cancers. 2025; 17(8):1327. https://doi.org/10.3390/cancers17081327

![Positron emission tomography (PET) scans showing evolution in time of the abdominal EIMS with large hypermetabolic mesenteric mass, associated with several hypermetabolic intraperitoneal nodules (A) A clear morpho-metabolic regression of the mesenteric mass and secondary intraperitoneal implants previously visualized 3 and 6 months after targeted therapy with alectinib (B,C). (A) Baseline. (B) After 3 months of alectinib. (C) After 6 months of alectinib.

Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory Myofibroblastic Tumour: State of the Art. Cancers. 2022; 14(15):3662. https://doi.org/10.3390/cancers14153662](attachment:0f66b1ef-4906-4ca6-935b-168bbe10645f:cancers-14-03662-g004.png)

Positron emission tomography (PET) scans showing evolution in time of the abdominal EIMS with large hypermetabolic mesenteric mass, associated with several hypermetabolic intraperitoneal nodules (A) A clear morpho-metabolic regression of the mesenteric mass and secondary intraperitoneal implants previously visualized 3 and 6 months after targeted therapy with alectinib (B,C). (A) Baseline. (B) After 3 months of alectinib. (C) After 6 months of alectinib.

Gros L, Dei Tos AP, Jones RL, Digklia A. Inflammatory Myofibroblastic Tumour: State of the Art. Cancers. 2022; 14(15):3662. https://doi.org/10.3390/cancers14153662